Real-World Perspectives in Managing CLL Treatment is organized by Healio, Purdue University, RedMedEd, Lymphoma Research Foundation (LRF).
Release date: May 18, 2023
Expiration date: May 18, 2024
Description:
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings—though of course beneficial for CLL patients—represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances in the use of cytogenetic and molecular tests to stratify risk and determine prognosis.
This interactive activity presents the points of view of doctors and patients on issues relating to current challenges in CLL care. Each point of view is followed by a brief discussion that will help oncologists and hematologist-oncologists select the most appropriate targeted therapies, taking into account patient genetics, treatment adverse events, and previous treatments.
Learning Objectives:
Upon completion of this activity, participants should be better able to:
• interpret the cytogenetic, molecular, and other standard staging tests used to define risk and prognosis for patients with CLL;
• distinguish between the indicated uses, mechanisms of action, and safety of current and emerging immunotherapeutic and targeted agents for patients with CLL;
• outline a treatment plan to achieve the deepest and most durable response while balancing the risk for toxicities in previously untreated CLL patients and patients with relapsed/refractory CLL; and
• evaluate emerging prospective and real-world data on novel treatment sequencing strategies for managing relapsed/refractory CLL and its potential implications on clinical practice.